Cargando…
Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study
BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD grou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/ https://www.ncbi.nlm.nih.gov/pubmed/32467559 http://dx.doi.org/10.12659/AOT.920041 |
_version_ | 1783544142876377088 |
---|---|
author | Albano, Laetitia Banas, Bernhard Lehner, Frank Glyda, Maciej Viklicky, Ondrej Schleibner, Stefan Brown, Malcolm Kamar, Nassim |
author_facet | Albano, Laetitia Banas, Bernhard Lehner, Frank Glyda, Maciej Viklicky, Ondrej Schleibner, Stefan Brown, Malcolm Kamar, Nassim |
author_sort | Albano, Laetitia |
collection | PubMed |
description | BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD groups, patients were randomized to one of 4 tacrolimus-based regimens (initial dose): Arm 1, immediate-release tacrolimus (0.2 mg/kg/day); Arm 2, prolonged-release tacrolimus (0.2 mg/kg/day); Arm 3, prolonged-release tacrolimus (0.3 mg/kg/day); Arm 4, prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab. All patients received mycophenolate mofetil and bolus corticosteroids; Arms 1–3 also received tapered corticosteroids. ECDs met the definition: living/deceased donors aged ≥60 years, or 50–60 years with ≥1 other risk factor, and donation after circulatory death. Primary composite endpoint: graft loss, biopsy-confirmed acute rejection or renal dysfunction by Day 168. Outcomes were compared across treatment arms with the chi-squared or Fisher’s exact test. RESULTS: A total of 1198 patients were included in the analysis (ECD: n=620 [51.8%], SCD: n=578 [48.2%]). Patients with kidneys from ECDs were older versus SCDs (mean age, 55.7 vs. 44.5 years, p<0.0001). A higher proportion of patients with kidneys from ECDs versus SCDs met the primary composite endpoint (56.8% vs. 32.4%, p<0.0001). However, no statistically significant differences in clinical outcomes or the incidence of treatment-emergent adverse events were seen between treatment arms within each donor group. CONCLUSIONS: Worse outcomes were experienced in patients who received kidneys from ECDs versus SCDs. Prolonged-release tacrolimus provided similar graft survival to the immediate-release formulation, with a manageable tolerability profile. CLINICAL TRIAL LINK: https://clinicaltrials.gov/ct2/show/NCT00717470?term=pmr-ec-1210&draw=2&rank=1 |
format | Online Article Text |
id | pubmed-7282531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72825312020-06-19 Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study Albano, Laetitia Banas, Bernhard Lehner, Frank Glyda, Maciej Viklicky, Ondrej Schleibner, Stefan Brown, Malcolm Kamar, Nassim Ann Transplant Original Paper BACKGROUND: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. MATERIAL/METHODS: Within the ECD and SCD groups, patients were randomized to one of 4 tacrolimus-based regimens (initial dose): Arm 1, immediate-release tacrolimus (0.2 mg/kg/day); Arm 2, prolonged-release tacrolimus (0.2 mg/kg/day); Arm 3, prolonged-release tacrolimus (0.3 mg/kg/day); Arm 4, prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab. All patients received mycophenolate mofetil and bolus corticosteroids; Arms 1–3 also received tapered corticosteroids. ECDs met the definition: living/deceased donors aged ≥60 years, or 50–60 years with ≥1 other risk factor, and donation after circulatory death. Primary composite endpoint: graft loss, biopsy-confirmed acute rejection or renal dysfunction by Day 168. Outcomes were compared across treatment arms with the chi-squared or Fisher’s exact test. RESULTS: A total of 1198 patients were included in the analysis (ECD: n=620 [51.8%], SCD: n=578 [48.2%]). Patients with kidneys from ECDs were older versus SCDs (mean age, 55.7 vs. 44.5 years, p<0.0001). A higher proportion of patients with kidneys from ECDs versus SCDs met the primary composite endpoint (56.8% vs. 32.4%, p<0.0001). However, no statistically significant differences in clinical outcomes or the incidence of treatment-emergent adverse events were seen between treatment arms within each donor group. CONCLUSIONS: Worse outcomes were experienced in patients who received kidneys from ECDs versus SCDs. Prolonged-release tacrolimus provided similar graft survival to the immediate-release formulation, with a manageable tolerability profile. CLINICAL TRIAL LINK: https://clinicaltrials.gov/ct2/show/NCT00717470?term=pmr-ec-1210&draw=2&rank=1 International Scientific Literature, Inc. 2020-05-29 /pmc/articles/PMC7282531/ /pubmed/32467559 http://dx.doi.org/10.12659/AOT.920041 Text en © Ann Transplant, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Original Paper Albano, Laetitia Banas, Bernhard Lehner, Frank Glyda, Maciej Viklicky, Ondrej Schleibner, Stefan Brown, Malcolm Kamar, Nassim Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title_full | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title_fullStr | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title_full_unstemmed | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title_short | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study |
title_sort | outcomes with tacrolimus-based immunosuppression after kidney transplantation from standard- and extended-criteria donors – a post hoc analysis of the prospective osaka study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/ https://www.ncbi.nlm.nih.gov/pubmed/32467559 http://dx.doi.org/10.12659/AOT.920041 |
work_keys_str_mv | AT albanolaetitia outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT banasbernhard outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT lehnerfrank outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT glydamaciej outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT viklickyondrej outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT schleibnerstefan outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT brownmalcolm outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy AT kamarnassim outcomeswithtacrolimusbasedimmunosuppressionafterkidneytransplantationfromstandardandextendedcriteriadonorsaposthocanalysisoftheprospectiveosakastudy |